Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/48249
Título: Unique SERM-like properties of the novel fluorescent tamoxifen derivative FLTX1
Autores/as: Marrero-Alonso, Jorge
Morales, Araceli
García Marrero, Benito
Boto, Alicia
Marín, Raquel
Cury, Débora
Gómez, Tomás
Fernández Pérez, Leandro 
Lahoz, Fernando
Díaz, Mario
Clasificación UNESCO: 32 Ciencias médicas
3209 Farmacología
Palabras clave: Selective estrogen receptor modulators (SERMs)
Estrogen receptor-positive breast cancer
Antiestrogens
Fluorescent derivatives
Estrogen-dependent cell proliferation, et al.
Fecha de publicación: 2013
Proyectos: Estudios de Nuevos Moduladores de Las Actividades de Stat y de Los Receptores Para Estrogenos: Potencial Aplicacion Como Antitumorales 
Publicación seriada: European Journal of Pharmaceutics and Biopharmaceutics 
Resumen: Tamoxifen is a selective estrogen receptor modulator extensively used on estrogen receptor-positive breast cancer treatment. However, clinical evidences demonstrate the increased incidence of undesirable side effects during chronic therapies, the most life threatening being uterine cancers. Some of these effects are related to tissue-dependent estrogenic actions of tamoxifen, but the exact mechanisms remain poorly understood. We have designed and synthesized a novel fluorescent tamoxifen derivative, FLTX1, and characterized its biological and pharmacological activities. Using confocal microscopy, we demonstrate that FLTX1 colocalizes with estrogen receptor alpha (ER alpha). Competition studies showed that FLTX1 binding was totally displaced by unlabeled tamoxifen and partially by estradiol, indicating the existence of non-ER-related triphenylethylene-binding sites. Ligand binding assays showed that FLTX1 exhibits similar affinity for ER than tamoxifen. FLTX1 exhibited antiestrogenic activity comparable to tamoxifen in MCF7 and T47D cells transfected with 3xERE-luciferase reporter. Interestingly, FLTX1 lacked the strong agonistic effect of tamoxifen on ER alpha-dependent transcriptional activity. Additionally, in vivo assays in mice revealed that unlike tamoxifen, FLTX1 was devoid of estrogenic uterotrophic effects, lacked of hyperplasic and hypertrophic effects, and failed to alter basal proliferating cell nuclear antigen immunoreactivity. In the rat uterine model of estrogenicity/antiestrogenicity, FLTX1 displayed antagonistic activity comparable to tamoxifen at lower doses, and only estrogenic uterotrophy at the highest dose. We conclude that the fluorescent derivative FLTX1 is not only a suitable probe for studies on the molecular pharmacology of tamoxifen, but also a potential therapeutic substitute to tamoxifen, endowed with potent antiestrogenic properties but devoid of uterine estrogenicity.
URI: http://hdl.handle.net/10553/48249
ISSN: 0939-6411
DOI: 10.1016/j.ejpb.2013.04.024
Fuente: European Journal of Pharmaceutics and Biopharmaceutics [ISSN 0939-6411], v. 85 (3, Part B), p. 898-910
Colección:Artículos
Vista completa

Citas SCOPUSTM   

18
actualizado el 24-mar-2024

Citas de WEB OF SCIENCETM
Citations

18
actualizado el 25-feb-2024

Visitas

64
actualizado el 23-mar-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.